-
Mashup Score: 1
InSilicoTrials will make use of Microsoft Azure’s cloud infrastructure and AI proficiencies to promote its digital simulation platform.
Source: www.mobihealthnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 17Chronic GVHD: one more promising player enters the arena - 16 day(s) ago
In this issue of Blood, Zhao et al report excellent overall responses and acceptable safety of a first-in-class JAK/ROCK inhibitor in a prospective phase 1
Source: ashpublications.orgCategories: General Medicine NewsTweet
-
Mashup Score: 0Social media and clinical trials: The pros and cons gain context when the patient is at the center - 20 day(s) ago
Social media is a useful tool for increasing awareness and disseminating information about clinical trials. However, risks include issues with confidentiality, privacy, and integrity of clinical tria…
Categories: General Medicine NewsTweet
-
Mashup Score: 63A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM - 30 day(s) ago
Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several…
Source: www.nejm.orgCategories: General Medicine NewsTweet
-
Mashup Score: 63A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM - 1 month(s) ago
Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several…
Source: www.nejm.orgCategories: General Medicine NewsTweet
-
Mashup Score: 63A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM - 1 month(s) ago
Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several…
Source: www.nejm.orgCategories: General Medicine NewsTweet
-
Mashup Score: 0Social media and clinical trials: The pros and cons gain context when the patient is at the center - 2 month(s) ago
Social media is a useful tool for increasing awareness and disseminating information about clinical trials. However, risks include issues with confidentiality, privacy, and integrity of clinical tria…
Categories: General Medicine NewsTweet
-
Mashup Score: 0
The average number of industry-funded trials started per month was 135.8 before the IRA was passed and 83.6 after — a 38.4% decrease.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Toxicity in phase 3 cancer trials often unreported, minimized - 3 month(s) ago
Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its impact, according to findings published in JCO Oncology Practice.“We publish a lot of studies that don’t necessarily consider the patients’ perspective, but they are the people who are ultimately impacted by the results of our studies,” Avital M. Miller,
Source: www.healio.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Purpose Patients with organ dysfunction, prior or concurrent malignancies, and comorbidities are often excluded from clinical trials. Excluding patients on the basis of these factors results in clinical trial participants who are healthier and younger than the overall population of patients with cancer. Methods ASCO and Friends of Cancer Research established a multidisciplinary working group that included experts in trial design and conduct to examine how eligibility criteria could be more inclusive. The group analyzed current eligibility criteria; conducted original data analysis; considered safety concerns, potential benefits, research, and potential hurdles of this approach through discussion; and reached consensus on recommendations regarding updated eligibility criteria that prioritize inclusiveness without compromising patient safety. Results If renal toxicity and clearance are not of direct treatment-related concern, then patients with lower creatinine clearance values of > 30 m
Source: ascopubs.orgCategories: General Medicine NewsTweet
.@InSilicoTrials becomes part of Microsoft for Startups Pegasus @msft4startups Program - will make use of Microsoft Azure's cloud infrastructure and AI proficiencies to promote its digital simulation platform | #clinicaltrials https://t.co/VYSAVFCxRX